A research group led by Tsubasa Takizawa, a full-time lecturer at Keio University, has shown that a new anti-migraine drug, a CGRP-related antibody drug, is likely to be effective in patients who are older, have a lower number of prophylactic drug failures, and have no history of immune system disease. clarified.

 Migraine is a common disease with a prevalence of 8.4%.In recent years, a calcitonin gene-related peptide (CGRP)-related antibody drug has been developed as a prophylactic therapy for migraine.Although it is more effective than conventional drugs, it is relatively expensive (approximately 3 yen per month at a 13,000% copayment) and can cause side effects such as injection site reactions and constipation, so optimization of prescription is desired.Although there have been Western paper reports on what kind of patients (responders) her CGRP-related antibody drug is effective for, there has been no paper report in Japan.

 This time, the research group examined 3 patients (101 galcanezumab, 57 fremanezumab, 31 elenumab) who started CGRP-related antibody drugs and continued treatment for more than 13 months among the outpatients of Keio University Hospital for migraine. ).Responders were defined as those whose number of migraine days had decreased by more than half compared to before the start of treatment 3 months after the start of treatment, and non-responders were defined as others.

 As a result, it is clear that (XNUMX) older patients, (XNUMX) fewer failures of prophylactic drugs, and (XNUMX) patients with no history of immune system disease are more likely to be responders to CGRP-related antibody drugs (= CGRP-related antibody drugs are more likely to be effective). became.

 Among the results obtained this time, there are already several similar research reports from Europe and the United States regarding the number of preventive drug failures. Regarding "age", there are aspects that differ from previous reports, and there are few past reports regarding medical history, so further investigation is necessary in the future.

Paper information:[The Journal of Headache and Pain] Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study

Keio University

University Journal Online Editorial Department

This is the online editorial department of the university journal.
Articles are written by editorial staff who have a high level of knowledge and interest in universities and education.